Use of Milnacipran in a Patient with Hyponatremia under the Cover of Fludrocortisones
|Sandeep Grover1*, Mansi Somaiya2 and Pinaki Dutta3|
|1Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India|
|2BYL Nair Ch. Hospital & T. N. Medical College, Mumbai, India|
|3Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India|
|Corresponding Author :||Sandeep Grover
Department of Psychiatry
Postgraduate Institute of Medical Education & Research
Chandigarh 160012, India
E-mail: [email protected]
|Received July 29, 2013; Accepted October 28, 2013; Published October 31, 2013|
|Citation: Grover S, Somaiya M, Dutta P (2013) Use of Milnacipran in a Patient with Hyponatremia under the Cover of Fludrocortisones. J Clin Case Rep 3:308. doi:10.4172/2165-7920.1000308|
|Copyright: © 2013 Grover S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Introduction: Hyponatremia is a known side effect of antidepressant medications.Usually management of hyponatremia in patients receiving antidepressants involves stopping of antidepressant and restriction of fluid intake. However, information is not clear with respect to use of antidepressant in patients with persistent hyponatremia.
Objective: To describe a patient detected to have hyponatremia prior to starting of antidepressant. The hyponatremia was corrected with the use of fludrocortisone, but introduction of sertraline led to reemergence of hyponatremia. Later patient tolerated milnacipran along with fludrocortisone, without recurrence of hyponatremia.
Conclusion: Fludrocortisone can be used for prevention and management of hyponatremia in patients at high risk of developing the same. Further, milnacipran may be considered as a viable option in patients who develop hyponatremia with SSRIs